|
1
|
Rebucci M and Michiels C: Molecular
aspects of cancer cell resistance to chemotherapy. Biochem
Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weisberg E, Manley PW, Cowan-Jacob SW,
Hochhaus A and Griffin JD: Second generation inhibitors of BCR-ABL
for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer. 7:345–356. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gately DP and Howell SB: Cellular
accumulation of the anticancer agent cisplatin: A review. Br J
Cancer. 67:1171–1176. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loh SY, Mistry P, Kelland LR, Abel G and
Harrap KR: Reduced drug accumulation as a major mechanism of
acquired resistance to cisplatin in a human ovarian carcinoma cell
line: Circumvention studies using novel platinum (II) and (IV)
ammine/amine complexes. Br J Cancer. 66:1109–1115. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scanlon KJ, Kashani-Sabet M, Tone T and
Funato T: Cisplatin resistance in human cancers. Pharmacol Ther.
52:385–406. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hosking LK, Whelan RD, Shellard SA,
Bedford P and Hill BT: An evaluation of the role of glutathione and
its associated enzymes in the expression of differential
sensitivities to antitumour agents shown by a range of human tumour
cell lines. Biochem Pharmacol. 40:1833–1842. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perego P, Giarola M, Righetti SC, Supino
R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and
Zunino F: Association between cisplatin resistance and mutation of
p53 gene and reduced bax expression in ovarian carcinoma cell
systems. Cancer Res. 56:556–562. 1996.PubMed/NCBI
|
|
10
|
Penning TM, Burczynski ME, Jez JM, Hung
CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K: Human
3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the
aldo-keto reductase superfamily: Functional plasticity and tissue
distribution reveals roles in the inactivation and formation of
male and female sex hormones. Biochem J. 351:67–77. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schlegel BP, Pawlowski JE, Hu Y, Scolnick
DM, Covey DF and Penning TM: Secosteroid mechanism-based
inactivators and site-directed mutagenesis as probes for steroid
hormone recognition by 3 alpha-hydroxysteroid dehydrogenase.
Biochemistry. 33:10367–10374. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bohren KM, Bullock B, Wermuth B and Gabbay
KH: The aldo-keto reductase superfamily. cDNAs and deduced amino
acid sequences of human aldehyde and aldose reductases. J Biol
Chem. 264:9547–9551. 1989.PubMed/NCBI
|
|
13
|
Hyndman D, Bauman DR, Heredia VV and
Penning TM: The aldo-keto reductase superfamily homepage. Chem Biol
Interact. 143-144:621–631. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin HK, Steckelbroeck S, Fung KM, Jones AN
and Penning TM: Characterization of a monoclonal antibody for human
aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid
dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase);
immunohistochemical detection in breast and prostate. Steroids.
69:795–801. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dozmorov MG, Azzarello JT, Wren JD, Fung
KM, Yang Q, Davis JS, Hurst RE, Culkin DJ, Penning TM and Lin HK:
Elevated AKR1C3 expression promotes prostate cancer cell survival
and prostate cell-mediated endothelial cell tube formation:
Implications for prostate cancer progression. BMC Cancer.
10:6722010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miller VL, Lin HK, Murugan P, Fan M,
Penning TM, Brame LS, Yang Q and Fung KM: Aldo-keto reductase
family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and
squamous cell carcinoma but not small cell carcinoma. Int J Clin
Exp Pathol. 5:278–289. 2012.PubMed/NCBI
|
|
17
|
Martinez I, Wang J, Hobson KF, Ferris RL
and Khan SA: Identification of differentially expressed genes in
HPV-positive and HPV-negative oropharyngeal squamous cell
carcinomas. Eur J Cancer. 43:415–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang HW, Lin CP, Chiu JH, Chow KC, Kuo KT,
Lin CS and Wang LS: Reversal of inflammation-associated dihydrodiol
dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug
resistance in nonsmall cell lung cancer cells by wogonin and
chrysin. Int J Cancer. 120:2019–2027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng HB, Adikari M, Parekh HK and Simpkins
H: Ubiquitous induction of resistance to platinum drugs in human
ovarian, cervical, germ-cell and lung carcinoma tumor cells
overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Cancer Chemother Pharmacol. 54:301–307. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Negoro K, Yamano Y, Fushimi K, Saito K,
Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, et al:
Establishment and characterization of a cisplatin-resistant cell
line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol.
30:1325–1332. 2007.PubMed/NCBI
|
|
21
|
Byrns MC, Steckelbroeck S and Penning TM:
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a
selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD,
type 5 17beta-HSD, and prostaglandin F synthase), a potential
target for the treatment of hormone dependent and hormone
independent malignancies. Biochem Pharmacol. 75:484–493. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bauman DR, Rudnick SI, Szewczuk LM, Jin Y,
Gopishetty S and Penning TM: Development of nonsteroidal
anti-inflammatory drug analogs and steroid carboxylates selective
for human aldo-keto reductase isoforms: Potential antineoplastic
agents that work independently of cyclooxygenase isozymes. Mol
Pharmacol. 67:60–68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsunaga T, Tsuji Y, Kaai K, Kohno S,
Hirayama R, Alpers DH, Komoda T and Hara A: Toxicity against
gastric cancer cells by combined treatment with 5-fluorouracil and
mitomycin c: Implication in oxidative stress. Cancer Chemother
Pharmacol. 66:517–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
26
|
Matsunaga T, Hojo A, Yamane Y, Endo S,
El-Kabbani O and Hara A: Pathophysiological roles of aldo-keto
reductases (AKR1C1 and AKR1C3) in development of cisplatin
resistance in human colon cancers. Chem Biol Interact. 202:234–242.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Novotna R, Wsol V, Xiong G and Maser E:
Inactivation of the anticancer drugs doxorubicin and oracin by
aldo-keto reductase (AKR) 1C3. Toxicol Lett. 181:1–6. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chirino YI and Pedraza-Chaverri J: Role of
oxidative and nitrosative stress in cisplatin-induced
nephrotoxicity. Exp Toxicol Pathol. 61:223–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang G, Reed E and Li QQ: Molecular basis
of cellular response to cisplatin chemotherapy in non-small cell
lung cancer (Review). Oncol Rep. 12:955–965. 2004.PubMed/NCBI
|
|
30
|
Ebert B, Kisiela M, Wsól V and Maser E:
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3,
AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and
HT-29. Chem Biol Interact. 191:239–249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parker JB and Stivers JT: Dynamics of
uracil and 5-fluorouracil in DNA. Biochemistry. 50:612–617. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Byrns MC, Jin Y and Penning TM: Inhibitors
of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and
structural insights. J Steroid Biochem Mol Biol. 125:95–104. 2011.
View Article : Google Scholar : PubMed/NCBI
|
